This site is intended for US healthcare professionals only.

INDICATIONS

XPOVIO® (selinexor) is a prescription medicine approved:

  • in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma (MM) who have received at least one prior therapy.

IMPORTANT SAFETY INFORMATION

Thrombocytopenia: XPOVIO can cause life-threatening
thrombocytopenia, potentially leading to hemorrhage.
Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL.